Jonathan Olefson Joins as General Counsel and Corporate Secretary Robert Parks Joins as Chief Accounting Officer RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research
Highlights GAAP total revenue of $1.11 billion and $3.24 billion for the three and nine months ended September 30, 2018, respectively. Combined Company ASC 606 adjusted service revenue of $1.12 billion and $3.26 billion for the three and nine months ended September 30, 2018, respectively.
RALEIGH, N.C. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer Alistair
Award Season Wins Include Industry Recognition for Digital, Print, Video and Social Media Campaigns COLUMBUS, Ohio, Oct. 25, 2018 (GLOBE NEWSWIRE) -- GSW, a Syneos Health TM Company and industry leader in healthcare advertising, was named Agency of the Year (AOY) in the 2018 Healthcare Marketing
RALEIGH, N.C. , Oct. 19, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), will release its third quarter 2018 financial results on
Original Research to Be Presented at Digital Pharma East RALEIGH, N.C. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (NASDAQ:SYNH), the only fully integrated biopharmaceutical solutions organization, today released a study providing real-world patient insights into the effectiveness of
Investigative Sites Recognize Company’s Leadership in Advancing Clinical Research Through Collaborative Site Relationships RALEIGH, N.C. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it
Addition of Market Leading Advisory and Operational Solutions Provider Increases High-Value Offerings and Expands Operational Scale in Key Growth Markets RALEIGH, N.C. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq:SYNH) (“Syneos Health” or “the Company”), a leading
RALEIGH, N.C. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Financial Officer Jason
RALEIGH, N.C. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced the pricing of
RALEIGH, N.C. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that
Highlights GAAP total revenue of $1.07 billion and $2.13 billion for the three and six months ended June 30, 2018, respectively. Combined Company ASC 606 adjusted service revenue of $1.08 billion and $2.14 billion for the three and six months ended June 30, 2018, respectively.
RALEIGH, N.C. , July 12, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO ( Contract Commercial Organization ), will release its second quarter 2018 financial results on
Company to Host Annual Site Appreciation Reception to Recognize the Critical Role of Clinical Research Sites in Drug Development RALEIGH, N.C , June 22, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced an
AUSTIN, Texas and RALEIGH, N.C., June 21, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research , the only platform that brings clinical research direct to clinical health care, are entering a strategic
BOSTON , June 05, 2018 (GLOBE NEWSWIRE) -- The tenth annual Dealmakers’ Intentions Study from Syneos Health Consulting , an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that the dealmaking environment will continue to accelerate with buyers becoming
Company to Release 10th Annual Dealmakers’ Intentions Survey, Providing Forward-Looking Perspectives on Biopharmaceutical Licensing and Acquisitions RALEIGH, N.C. , June 05, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization
RALEIGH, N.C. , May 21, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that Chief Executive Officer Alistair
Highlights Combined Company ASC 605 net new business awards of $872.1 million for the first quarter of 2018 representing a book-to-bill ratio of 1.15x. — Clinical Solutions awards of $549.7 million , resulting in first quarter of 2018 and trailing 12-month book-to-bill ratios of 1.04x and 1.21x,
Meggs Served as Interim CFO Since February 2018 RALEIGH, N.C. , May 09, 2018 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO ( Contract Commercial Organization ), today announced that
RALEIGH, N.C. , May 03, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO ( Contract Commercial Organization ), today announced that Amy J.
New Network Builds on Success of the Company’s Early Phase, Oncology, Psychiatry and Vaccine Catalyst Site Networks RALEIGH, N.C. , April 30, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the launch of the
RALEIGH, N.C. , April 17, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO ( Contract Commercial Organization ), will release its first quarter 2018 financial results on Wednesday, May 9, 2018 , prior
Syneos Health Joins Align Clinical CRO as Founding Member to Continue the Company’s Focus on Shortening the Distance from Lab to Life™ RALEIGH, N.C. , March 27, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced
RALEIGH, N.C. , March 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the Barclays Global Healthcare Conference in Miami . Mr.
Highlights Combined Company net new business awards of $622.9 million for the fourth quarter and $2.55 billion for the full year 2017 representing growth of 16.5% for the full year 2017. Combined Company book-to-bill ratio of 1.16x for the fourth quarter and 1.20x for the full year 2017.
RALEIGH, N.C. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, has announced the appointment of Lisa van Capelle as Chief Human Resources Officer (CHRO). van Capelle will guide a workforce of approximately 21,000
New Data from Global Survey Reveals Expectations and Concerns of Patients and Caregivers Confronting a Future with Artificial Intelligence RALEIGH, N.C. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Syneos Health Communications today released a report that provides pioneering perspectives into patients’
RALEIGH, N.C. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and year end 2017 financial results on Wednesday, February 28, 2018 , prior to its earnings call at 8:00 a.m.
Joining Forces Brings Unparalleled Talent Together Under Top Leadership, Drives Scale for East Coast Operations and Expands West Coast Biopharma and Medtech Offerings RALEIGH, N.C. , Jan. 22, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (NASDAQ:SYNH), the only fully integrated biopharmaceutical
The Commercial Forecast Joins a Series of Consumer, Digital, Communications and Healthcare Trends Reports that Reveals Shifts in Media and Medicine Impacting Stakeholder Engagement RALEIGH, N.C. , Jan. 10, 2018 (GLOBE NEWSWIRE) -- Syneos Health TM (NASDAQ:SYNH), the only fully integrated
New Identity Signifies Industry’s Only Fully Integrated, End-to-End Biopharmaceutical Solutions Organization RALEIGH, N.C. , Jan. 04, 2018 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq:INCR) today announced it has changed its brand identity to Syneos Health, Inc.
Greg Rush to Step Down as Chief Financial Officer to Pursue Another Opportunity RALEIGH, N.C. , Jan. 03, 2018 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Greg Rush is stepping down as Chief
